Yoshitsugu Kiyoshi, Yamada Kazuo, Toyota Tomoko, Aoki-Suzuki Mika, Minabe Yoshio, Nakamura Kazuhiko, Sekine Yoshimoto, Suzuki Katsuaki, Takei Noriyoshi, Itokawa Masanari, Mori Norio, Yoshikawa Takeo
Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Wako, Saitama, Japan.
Psychiatry Res. 2006 Dec 7;145(2-3):249-58. doi: 10.1016/j.psychres.2005.10.013. Epub 2006 Oct 30.
The present study explored minor physical anomaly items relevant to schizophrenia in order to establish a scale that can distinguish schizophrenia from controls using newly identified items along with items from the refined Waldrop scale. Seven items were significantly more frequent among schizophrenia patients (N=218) than controls (N=226). Among these seven items, two novel features, strabismus and 'cuspidal ear' showed markedly different prevalence rates between schizophrenia and control groups. A six-item scale, including the newly identified strabismus and cuspidal ear, was selected for most accurately discriminating patients with schizophrenia from controls. This scale correctly classified 59.6% of patients and 78.9% of control subjects. This new scale is procedurally more exacting and quantitative, and more relevant to schizophrenia than the original Waldrop scale. The validity of this scale should be sound since it was tested on a larger number of cohorts than used in previous research. Our scale can be used as a biomarker for predicting risk for future development of schizophrenia. The scale may also facilitate the identification of schizophrenia susceptibility genetic/environmental factors by stratifying etiologically heterogeneous patients according to physical abnormalities.
本研究探索了与精神分裂症相关的轻微身体异常项目,以便建立一个量表,该量表能够使用新识别的项目以及经过改进的沃尔德罗普量表中的项目,将精神分裂症患者与对照组区分开来。在218名精神分裂症患者中,有七个项目的出现频率显著高于226名对照组。在这七个项目中,斜视和“尖耳”这两个新特征在精神分裂症组和对照组之间的患病率有明显差异。为了最准确地将精神分裂症患者与对照组区分开来,选择了一个包含新识别出的斜视和尖耳的六项量表。该量表正确分类了59.6%的患者和78.9%的对照者。这个新量表在程序上更严格、更具定量性,并且比原始的沃尔德罗普量表与精神分裂症的相关性更强。由于该量表在比以往研究更多的队列中进行了测试,其有效性应该是可靠的。我们的量表可以用作预测精神分裂症未来发病风险的生物标志物。该量表还可能通过根据身体异常对病因异质性患者进行分层,促进精神分裂症易感性遗传/环境因素的识别。